Our Pricing

The Science Behind Mounjaro What Is It

Understanding what is Mounjaro how does it work UK begins with its active ingredient tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management. At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance on this breakthrough treatment, with transparent pricing from £135.00 and free online consultations completed in under three minutes.

What Is Mounjaro? Understanding Tirzepatide's Unique Mechanism

Mounjaro contains tirzepatide, a novel medication that works differently from any previous weight loss treatment available in the UK. Unlike single-pathway GLP-1 receptor agonists such as semaglutide or liraglutide, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously [1]. This dual action creates a more comprehensive metabolic response than older treatments.

The GLP-1 component reduces appetite by acting on brain regions that control hunger, whilst also slowing gastric emptying to increase feelings of fullness after meals. The GIP receptor activation enhances insulin secretion and improves how your body processes nutrients, whilst also appearing to amplify the weight loss effects of GLP-1 stimulation [1]. This dual mechanism explains why clinical trials have consistently shown greater weight reduction with tirzepatide compared to single-receptor treatments.

Tirzepatide is administered as a once-weekly subcutaneous injection using the Mounjaro KwikPen device. The medication is gradually increased over several months, starting at 2.5mg weekly and potentially reaching maintenance doses of 5mg, 10mg, or 15mg depending on individual response and tolerability [2]. All dosing decisions require assessment by a UK-registered prescriber, who will evaluate your medical history, current medications, and weight management goals.

How Does Mounjaro Work for Weight Loss? The Clinical Evidence

The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated tirzepatide's remarkable efficacy in adults with obesity or overweight. Participants receiving the 15mg dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This represents one of the highest average weight reductions ever recorded in a pharmaceutical trial for obesity management.

Importantly, 91% of participants on the highest dose achieved at least 5% weight loss — the threshold considered clinically meaningful — and 57% achieved weight reduction of 20% or more [1]. These results surpassed those seen in comparable trials of semaglutide, though direct head-to-head studies are ongoing. The weight loss occurred alongside improvements in cardiovascular risk factors including blood pressure, cholesterol levels, and markers of inflammation.

The mechanism behind these results involves multiple physiological changes. Tirzepatide reduces energy intake by decreasing appetite and food cravings, whilst the slowed gastric emptying means you feel satisfied for longer after eating [2]. The medication also appears to increase energy expenditure slightly and may improve how efficiently your body burns stored fat. However, clinical trials emphasise that tirzepatide works best when combined with a reduced-calorie diet and increased physical activity.

What Happens During Treatment

After your UK prescriber approves treatment, you'll begin with the 2.5mg starter dose for four weeks. This gradual introduction helps minimise gastrointestinal side effects, which are the most commonly reported reactions to tirzepatide [2]. Your dose is then increased every four weeks until you reach an effective maintenance level, which your prescriber determines based on your weight loss progress and how well you tolerate the medication.

Most patients notice reduced appetite within the first week of treatment, though significant weight loss typically becomes apparent after 8-12 weeks. The SURMOUNT-1 trial showed weight reduction continued throughout the 72-week study period, suggesting long-term treatment produces sustained benefits [1]. Regular monitoring by your healthcare provider ensures treatment remains safe and effective as you progress.

Mounjaro vs Wegovy: Comparing Dual and Single Receptor Agonists

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are MHRA-licensed weekly injectable treatments for weight management, but their mechanisms differ significantly. Wegovy activates only GLP-1 receptors, whilst Mounjaro's dual GIP/GLP-1 action produces distinct metabolic effects [3]. In separate clinical trials, the highest Mounjaro dose showed greater average weight reduction (22.5%) compared to the highest Wegovy dose (14.9%), though these were not direct comparisons [1][3].

The choice between treatments depends on individual factors including medical history, previous treatment responses, and tolerability. Some patients who experience significant gastrointestinal side effects with one medication may tolerate the other better. Cost considerations also vary, with Wegovy priced from £135.00 at Cured Pharmacy compared to Mounjaro from £135.00. Your UK prescriber will discuss which option best suits your circumstances during your clinical assessment.

Both medications require commitment to lifestyle changes for optimal results. Neither is a standalone solution — clinical trial participants followed structured diet and exercise programmes alongside medication [1][3]. The MHRA licensing for both treatments specifies they should be used as part of a comprehensive weight management plan, not as substitutes for healthy behaviours.

Who Can Use Mounjaro? UK Prescribing Criteria and Eligibility

In the UK, Mounjaro is licensed for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. UK prescribers assess eligibility during a clinical consultation, reviewing your medical history, current medications, and previous weight management attempts.

Certain conditions preclude Mounjaro use. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. It should not be used during pregnancy or breastfeeding, and caution is required in patients with severe gastrointestinal disease, pancreatitis history, or diabetic retinopathy. Your prescriber will screen for these contraindications during assessment.

At Cured Pharmacy, our UK-registered clinical team conducts thorough online assessments before approving any prescription. This includes reviewing your weight history, understanding your weight loss goals, and ensuring Mounjaro is medically appropriate and safe for you. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical decisions, ensuring every prescription meets MHRA guidelines and professional standards.

Medical Conditions That Require Special Consideration

Patients with type 2 diabetes require careful monitoring when starting Mounjaro, as the medication significantly lowers blood glucose levels. If you take other diabetes medications, particularly insulin or sulfonylureas, your prescriber may need to adjust those doses to prevent hypoglycaemia [2]. Regular blood glucose monitoring becomes especially important during the first weeks of treatment.

Those with kidney disease may need dose adjustments or closer monitoring, though tirzepatide has been studied in patients with various degrees of renal impairment. Gastrointestinal conditions such as gastroparesis may be worsened by tirzepatide's effect on gastric emptying [4]. Your UK prescriber evaluates these factors individually to determine if Mounjaro is appropriate for your specific situation.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Mounjaro are gastrointestinal, occurring in approximately 60-80% of trial participants to some degree [1]. These include nausea, diarrhoea, decreased appetite, vomiting, constipation, and abdominal discomfort. Most gastrointestinal symptoms are mild to moderate in severity and typically diminish after several weeks as your body adjusts to the medication.

Starting with the low 2.5mg dose and increasing gradually every four weeks helps minimise these effects. Practical strategies include eating smaller, more frequent meals, avoiding high-fat foods that slow digestion further, staying well hydrated, and taking the injection on the same day each week [2]. If side effects become troublesome, your prescriber may slow the dose escalation or maintain you at a lower dose for longer before increasing.

Serious but rare side effects require immediate medical attention. These include severe abdominal pain that may indicate pancreatitis, changes in vision, signs of thyroid tumours (neck lump, difficulty swallowing, persistent hoarseness), severe allergic reactions, or symptoms of gallbladder problems [4]. The SURMOUNT trials showed pancreatitis occurred in less than 0.2% of participants, but patients should remain vigilant for warning signs [1].

When to Contact Your Healthcare Provider

Contact your prescriber if you experience persistent vomiting that prevents you from keeping down fluids, as this can lead to dehydration and kidney problems. Severe or persistent abdominal pain, especially if accompanied by vomiting, requires prompt evaluation to rule out pancreatitis [2]. Changes in mood, including thoughts of self-harm, have been reported rarely with GLP-1 receptor agonists and should be discussed with a healthcare professional immediately.

At Cured Pharmacy, our clinical team remains available to address concerns throughout your treatment. You can contact us on (+44) 116 4646009 during business hours, and we provide guidance on managing side effects or determining when additional medical review is necessary. All our clinicians are UK-registered and work under the supervision of superintendent pharmacist Tarun Kumar.

Getting Mounjaro Through Cured Pharmacy: The Process

Accessing Mounjaro through Cured Pharmacy begins with our free online consultation, which takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any contraindications. Our UK-registered prescribers review every assessment individually — this is not an automated approval process, but a genuine clinical evaluation by qualified healthcare professionals.

If approved, we dispense genuine UK-licensed Mounjaro from our GPhC-registered pharmacy (registration number 9012511). Pricing is transparent and shown upfront: Mounjaro starts from £135.00 depending on your prescribed dose. We offer discreet packaging and reliable delivery across the UK, with no hidden consultation fees. Unlike some services, you see the exact cost before completing your medical assessment.

Our service includes ongoing clinical support throughout your treatment. You can contact our pharmacy team with questions about administration technique, managing side effects, or when to seek additional medical review. We also provide follow-up consultations to assess your progress and determine whether dose adjustments are appropriate. This comprehensive approach ensures you receive not just medication, but complete pharmaceutical care from qualified UK professionals.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14881
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating overweight and obesity. Technology appraisal guidance [TA1003]. https://www.nice.org.uk/guidance/ta1003

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine and must be prescribed by a qualified clinician following appropriate clinical assessment.